RxDoctor Payments Data

Michael Mabry, DO

Family Medicine · Johnson City, TNNPI 1982130993

Payments from drug & device makers

$6,209in general payments, 2019–2025

Across 394 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$636
  • Novo Nordisk$520
  • GSK$511
  • Lilly USA, LLC$432
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$353
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,184100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,209 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$84,601
Medicare patients
133
Services billed
3,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$130,638
EliquisApixaban68$64,026
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$61,161
JardianceEmpagliflozin24$23,155
MounjaroTirzepatide19$20,017
FarxigaDapagliflozin Propanediol17$16,258
MyrbetriqMirabegron11$10,844
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$10,494
TrintellixVortioxetine Hydrobromide12$7,013
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$4,595
Omeprazole178$4,570
Gabapentin160$3,095
Buprenorphine12$2,567
ProgesteroneProgesterone, Micronized61$2,515
Levothyroxine Sodium293$2,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$520$130,638100 claims
PfizerEliquis$276$64,02668 claims
GSKTrelegy Ellipta$511$61,16162 claims
Boehringer IngelheimJardiance$96$23,15524 claims
Lilly USA, LLCMounjaro$432$20,01719 claims
AstraZenecaFarxiga$636$16,25817 claims
Astellas Pharma US IncMyrbetriq$138$10,84411 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$185$7,01312 claims
AbbVieSynthroid$1,114$2,21035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →